Noel Donnelly Biography and Net Worth

CFO of PepGen

Noel Donnelly serves as the Chief Financial Officer at PepGen. Prior to joining PepGen, Mr. Donnelly worked as the CFO at EIP Pharma Inc., a small private biotech in the neurodegenerative disease space. Before joining EIP Pharma, he spent 15 years at Shire PLC in various leadership within both research and development (R&D) and finance functions. More recently, Noel was Vice President, R&D Business Operations where he established and led key strategic processes and teams including R&D strategy, portfolio prioritization, due diligence and integrations. He previously held positions of increasing responsibility within the Shire finance organization, culminating as the Head of R&D Finance. Noel received his MBA with a Concentration in Finance from Babson College and his BS in Nuclear Engineering with a Minor in Economics from the University of Massachusetts-Lowell.

What is Noel Donnelly's net worth?: The estimated net worth of Noel Donnelly is at least $4.86 thousand as of February 26th, 2025. Mr. Donnelly owns 1,673 shares of PepGen stock worth more than $4,860 as of August 10th. This net worth estimate does not reflect any other assets that Mr. Donnelly may own. Learn More about Noel Donnelly's net worth.
How do I contact Noel Donnelly?: The corporate mailing address for Mr. Donnelly and other PepGen executives is , , . PepGen can also be reached via phone at 781-797-0979 and via email at [email protected]. Learn More on Noel Donnelly's contact information.
Has Noel Donnelly been buying or selling shares of PepGen?: Noel Donnelly has not been actively trading shares of PepGen during the last quarter. Most recently, Noel Donnelly sold 1,527 shares of the business's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $1.68, for a transaction totalling $2,565.36. Following the completion of the sale, the chief financial officer now directly owns 1,673 shares of the company's stock, valued at $2,810.64. Learn More on Noel Donnelly's trading history.
Who are PepGen's active insiders?: PepGen's insider roster includes Noel Donnelly (CFO), Kasra Kasraian (Revisit consent button Skip to Content PepGen Menu About Science EDO Platform Scientific Pub), James McArthur (President and Chief Executive Officer), and Paul Streck (Executive Vice President, Head of Research & Development). Learn More on PepGen's active insiders.
Are insiders buying or selling shares of PepGen?: During the last year, PepGen insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $640,000.00. During the last year, insiders at the sold shares 1 times. They sold a total of 1,233 shares worth more than $1,738.53. The most recent insider tranaction occured on May, 21st when insider Kasra Kasraian sold 1,233 shares worth more than $1,738.53. Insiders at PepGen own 1.3% of the company. Learn More about insider trades at PepGen.
Information on this page was last updated on 5/21/2026.

Noel Donnelly Insider Trading History at PepGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/26/2025	Sell	1,527	$1.68	$2,565.36	1,673

Noel Donnelly Buying and Selling Activity at PepGen

PepGen Company Overview

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Today's Range

Now: $2.90

$2.75

$2.95

50 Day Range

MA: $1.86

$1.35

$2.85

2 Week Range

Now: $2.90

$1.01

$7.80

Volume

899,236 shs

Average Volume

1,091,068 shs

Market Capitalization

$200.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89